Rovina Ruslami

International Publications
1. Ruslami, R.; H. Nijland, R. Aarnoutse, B. Alisjahbana, A. Y. Soeroto, S. Ewalds, and R. van Crevel. Evaluation of high- versus standard-dose rifampicin in Indonesian patients with pulmonary tuberculosis. Antimicrobial Agents Chemotherapy. 2006;56:822-823
2. Nijland, H. M. J., R. Ruslami, J. E. Stalenhoef, E. J. Nelwan, B. Alisjahbana, R. H. Nelwan, A. van der Ven, H. Danusantoso, R. E. Aarnoutse, and R. van Crevel. Exposure to rifampicin is strongly reduced in tuberculosis patients with type 2 diabetes. Clinical Infectious Disease. 2006;43:848-854
3. Nijland, H. M. J., R. E. Aarnoutse, R. Ruslami and R. van Crevel. Reply to Gadkowski and Stout. Clinical Infectious Disease. 2007;44:618-619
4. Ruslami, R., H. J. Nijland, B. Alisjahbana, I. Parwati, R. van Crevel, and R. E. Aarnoutse. Pharmacokinetics and tolerability of a higher rifampicin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrobial Agents and Chemotherapy. 2007;51:2546-2551
5. Nijland, H. M. J., R. Ruslami, A. J. Suroto, D. M. Burger, B. Alisjahbana, R. van Crevel, and R. E. Aarnoutse. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clinical Infectious Disease. 2007;45:1001-1007
6. Ruslami, R., R. van Crevel, E. van de Berge, B. Alisjahbana, and R. E. Aarnoutse. A step-wise approach to find a valid and feasible method to detect non-adherence to tuberculosis drugs. Southeast Asian Journal Tropical Medicine & Public Health. 2008;39:1083-1087
7. Ruslami R, Nijland HMJ, Adhiarta IGN, Kariadi SHKS, Alisjahbana B, Aarnoutse R, van Crevel R. Pharmacokinetics of anti tuberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrobial Agents & Chemotherapy. 2010;54:1068-1074
8. Ruslami R, Aarnoutse RE, Alisjahbana B, van der Ven A, van Crevel R. Implications of the global increase of diabetes for tuberculosis control and patient care. Tropical Medicine and International Health. 2010 Nov;15(11):1289-99.
9. Ruslami R, van Crevel R. Diabetes mellitus and tuberculosis treatment. Chapter book (vol. 40) of Progress in Respiratory Research - Antituberculosis Therapy. Karger AG. Basel, Switzerland. 2011.
10. Rutherford ME, Ruslami R, Maharani W, Yulita I, Lovell S, van Crevel R, Alisjahbana B, Hill PC. Adherence to isoniazid preventive therapy in Indonesian children: A quantitative and qualitative investigation. BMC Res Notes. 2012;5:7
11. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven A, Borm G, Aarnoutse RE, van Crevel R. Intensified antibiotic treatment for TB meningitis; a randomized controlled trial. Lancet Infectious Diseases. 2013;13;27-35.
12. Rutherford ME, Hill PC, Maharani W, Apriani L, Sampurno H, van Crevel R, Ruslami R. Risk factors for mycobacterium tuberculosis infection in Indonesian children living with a sputum smear-positive case. International Journal of Tuberculosis and Lung Disease. 2012;16(12):1594-99
13. Burhan E, Ruessen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van Crevel R, Aarnoutse R. Isoniazid, rifampin, and pyrazinamide plasma concetration in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrobi Agents Chemother. 2013 Aug;57(8):3614-9
14. Ruslami R, Ganiem AR, Aarnoutse RE, van Crevel R, study team. Rifampicin and moxifloxacin for tuberculosis meningitis-authors’ reply. Lancet Infect Dis. 2013 Jul;13(7)570
15. Rutherford ME, Hill PC, Maharani W, Sampurno H, Ruslami R. Risk factors for treatment default among adult tuberculosis patients in Indonesia.. Int J Tuberc Lung Dis. 2013 Oct;17(10):1304-9
16. Rutherford ME, Ruslami R, Anselmo M, Alisjahbana B, Yulianti N, Sampurno H, van Crevel R, Hill P. Management of children exposed to Mycobacterium tuberculosis: a public health evaluation in West Java, Indonesia. Bulletin of the WHO. Sept, 2013.
17. Rob Aarnoutse, Carolien Ruesen, Erlina Burhan, Reinout van Crevel, Rovina Ruslami. 2014. Reply to “Strategy To Limit Sampling of Antituberculosis Drugs Instead of Determining Concentrations at Two Hours Post ingestion in Relation to Treatment Response”, Antimicrobial Agents and Chemotherapy. 58(1):629–630.
18. van Crevel R, Dockrell HM; TANDEM Consortium. TANDEM: understanding diabetes and tuberculosis. Lancet Diabetes Endocrinology. 2014 Apr;2(4):270-2
19. Riza AL, Pearson F, Ugarte-Gil C, Alisjahbana B, van de Vijver S, Panduru NM, Hill PC, Ruslami R, Moore D, Aarnoutse R, Critchley JA, van Crevel R. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinology. 2014 Sep;2(9):740-53.
20. Te Brake L, Dian S, Ganiem AR, Ruesen C, Burger D, Donders R, Ruslami R, van Crevel R, Aarnoutse R. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. International Journal of Antimicrobial Agents. 2015 May;45(5):496-503.
21. te Brake LH, Ruslami R, Later-Nijland H, Mooren F, Teulen M, Apriani L, Koenderink JB, Russel FG, Burger DM, Alisjahbana B, Wieringa F, van Crevel R, Aarnoutse RE. Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients. Antimicrobial Agents & Chemotherapy. 2015 Jun;59(6):3233-9
22. Savic RM, Ruslami R, Hibma JE, Hesseling A, Ramachandran G, Ganiem AR, Swaminathan S, McIlleron H, Gupta A, Thakur K, van Crevel R, Aarnoutse R, Dooley KE. Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Clinical Pharmacology & Therapy. 2015 Dec;98(6):622-9
23. Bahr NC, Marais S, Caws M, van Crevel R, Wilkinson RJ, Tyagi JS, Thwaites GE, Boulware DR. Tuberculous Meningitis International Research Consortium. GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but not the Last. Clinical Infectious Disease. 2016;62(9):1133-5
24. van Crevel R, Ruslami R, Aarnoutse R. Therapy for Tuberculous Meningitis. New England Journal Medicine. 2016 Jun 2;374(22):2187
25. Yunivita V, Dian S, Ganiem AR, Hayati E, Achmad TH, Dewi AP, Teulen M, Meijerhof-Jager P, van Crevel R, Aarnoutse R, Ruslami R. Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculosis meningitis patients. International Journal of Antimicrobial Agents. 2016 Oct;48(4):415-21
26. Ruslami R, Menzies D. Finding the right dose of rifampicin, and the right dose of optimism. Lancet Inf Dis 2016; Lancet Infect Dis. 2017 Jan;17(1):2-3
27. Marais BJ, Heemskerk AD, Marais SS, van Crevel R, Rohlwink U, Caws M, Meintjes G, Misra UK, Mai NTH, Ruslami R, Seddon JA, Solomons R, van Toorn R, Figaji A, McIlleron H, Aarnoutse R, Schoeman JF, Wilkinson RJ, Thwaites GE. Tuberculous Meningitis International Research Consortium. Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies. Clinical Infectious Disease. 2017 Feb 15;64(4):501-509
28. van Laarhoven A, Dian S, Ruesen C, Hayati E, Damen MSMA, Annisa J, Chaidir L, Ruslami R, Achmad TH, Netea MG, Alisjahbana B, Rizal Ganiem A, van Crevel R. Clinical Parameters, Routine Inflammatory Markers, and LTA4H Genotype as Predictors of Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia. Journal Infectious Diseases. 2017 Apr 1;215(7):1029-1039
29. Koesoemadinata RC, McAllister SM, Soetedjo NNM, Ratnaningsih DF, Ruslami R, Kerry S, Verrall AJ, Apriani L, van Crevel R, Aisjahbana B, Hill PC. Latent tuberculosis infection and pulmonary tuberculosis disease among diabetes mellitus patients in Bandung, Indonesia. Transaction of the Royal Society Tropical Medicine & Hygiene 2017;111:81-9
30. van Laarhoven A, Dian S, Aguirre-Gamboa R, Avila-Pacheco J, Ricaño-Ponce I, Ruesen C, Annisa J, Koeken VACM, Chaidir L, Li Y, Achmad TH, Joosten LAB, Notebaart RA, Ruslami R, Netea MG, Verbeek MM, Alisjahbana B, Kumar V, Clish CB, Ganiem AR, van Crevel R. Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study. Lancet Infect Dis. 2018 May;18(5):526-535
31. Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, Requena-Méndez A, Peloquin C, Koegelenberg CFN, Alffenaar JWC, Ruslami R, Tostmann A, Swaminathan S, McIlleron H, Davies G. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother. 2018 Apr 26
32. Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li PZ, Hill PC, Schwartzman K, Benedetti A, Menzies D. Safety and Side Effects of Rifampin versus Isoniazid in Children. N Engl J Med. 2018 Aug 2;379(5):454-463
33. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med. 2018 Aug 2;379(5):440-453
34. Koesoemadinata RC, Kranzer K, Livia R, Susilawati N, Annisa J, Soetedjo NNM, Ruslami R, Philipsen R, van Ginneken B, Soetikno RD, van Crevel R, Alisjahbana B, Hill PC. Computer-assisted chest radiography reading for tuberculosis screening in people living with diabetes mellitus. Int J Tuberc Lung Dis. 2018 Sep 1;22(9):1088-1094
35. Soetedjo NNM, McAllister SM, Ugarte-Gil C, Firanescu AG, Ronacher K, Alisjahbana B, Costache AL, Zubiate C, Malherbe ST, Koesoemadinata RC, Laurence YV, Pearson F, Kerry-Barnard S, Ruslami R, Moore DAJ, Ioana M, Kleynhans L, Pernama H, Hill PC, Mota M, Walzl G, Dockrell HM, Critchley JA, van Crevel R; TANDEM consortium (members listed in full in Supplementary File). Disease characteristics and treatment of patients with diabetes mellitus attending government health services in Indonesia, Peru, Romania and South Africa. Trop Med Int Health. 2018 Aug 14
36. Chaidir L, Ruesen C, Dutilh BE, Ganiem AR, Andryani A, Apriani L, Huynen MA, Ruslami R, Hill PC, Crevel RV, Alisjahbana B. Use of whole genome sequencing to predict Mycobacterium tuberculosis drug resistance in Indonesia. J Glob Antimicrob Resist. 2018 Aug 29. pii: S2213-7165(18)30165-6. doi: 10.1016/j.jgar.2018.08.018. [Epub ahead of print.
37. Heemskerk AD, Donovan J, Thu DDA, Marais S, Chaidir L, Dung VTM, Centner CM, Ha VTN, Annisa J, Dian S, Bovijn L, Mai NTH, Phu NH, Chau NVV, Ganiem AR, Van CT, Geskus RB, Thuong NTT, Ruslami R, Meintjes G, van Crevel R, Wilkinson RJ, Thwaites GE. Improving the microbiological diagnosis of tuberculous meningitis: a prospective, international, multicentre comparison of conventional and modified Ziehl-Neelsen stain, GeneXpert, and culture of cerebrospinal fluid. J Infect. 2018 Dec;77(6):509-515. doi: 10.1016/j.jinf.2018.09.003. Epub 2018Sep 12.
38. Te Brake LHM, Yunivita V, Livia R, Soetedjo N, van Ewijk-Beneken Kolmer E, Koenderink JB, Burger DM, Santoso P, van Crevel R, Alisjahbana B, Aarnoutse RE, Ruslami R; TANDEM consortium. Rifampicin alters metformin plasma exposure but not blood glucose levels in diabetic tuberculosis patients. Clin Pharmacol Ther. 2018 Sep 17. doi: 10.1002/cpt.1232. [Epub ahead of print]
39. Dian S, Yunivita V, Ganiem AR, Pramaesya T, Chaidir L, Wahyudi K, Achmad TH, Colbers A, Te Brake L, van Crevel R, Ruslami R, Aarnoutse R. A double-blinded randomised placebo-controlled phase II trial to evaluate high dose rifampicin for tuberculous meningitis: a dose finding study. Antimicrob Agents Chemother. 2018 Sep 17. pii: AAC.01014-18. doi: 10.1128/AAC.01014-18. [Epub ahead of print]
40. Grint D, Alisjhabana B, Ugarte-Gil C, Riza AL, Walzl G, Pearson F, Ruslami R, Moore DAJ, Ioana M, McAllister S, Ronacher K, Koeseomadinata RC, Kerry-Barnard SR, Coronel J, Malherbe ST, Dockrell HM, Hill PC, Van Crevel R, Critchley JA; TANDEM consortium. Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa. Bull World Health Organ. 2018 Nov 1;96(11):738-749
41. Cresswell FV, Te Brake L, Atherton R, Ruslami R, Dooley KE, Aarnoutse R, Van Crevel R. Intensified antibiotic treatment of tuberculosis meningitis. Expert Rev Clin Pharmacol. 2019 Mar;12(3):267-288
42. van Laarhoven A, Dian S, van Dorp S, Purnama F, Koeken VACM, Diandini E, Utami F, Livia R, Apriani L, Ardiansyah E, Ter Horst R, Netea MG, Achmad TH, Hill PC, Ruslami R, Alisjahbana B, Ussher JE, Indrati A, Verrall A, Ganiem AR, van Crevel R. Immune cell characteristics and cytokine responses in adult HIV-negative tuberculous meningitis: an observational cohort study. Sci Rep. 2019 Jan 29;9(1):884.
43. Apriani L, McAllister S, Sharples K, Alisjahbana B, Ruslami R, Hill PC, Menzies D. Latent tuberculosis infection in health care workers in low and middle-income countries: an updated systematic review. Eur Respir J. 2019 Feb 20. pii: 1801789. doi: 10.1183/13993003.01789-2018. [Epub ahead of print]
44. Huangfu P, Laurence YV, Alisjahbana B, Ugarte-Gil C, Riza AL, Walzl G, Ruslami R, Moore DAJ, Ioana M, McAllister S, Ronacher K, Koesoemadinata RC, Grint D, Kerry S, Coronel J, Malherbe ST, Griffiths U, Dockrell HM, Hill PC, van Crevel R, Pearson F, Critchley JA. Point of care HbA1c level for diabetes mellitus management and its accuracy among tuberculosis patients: a study in four countries. Int J Tuberc Lung Dis. 2019 Mar 1;23(3):283-292
45. Oxlade O, Trajman A, Benedetti A, Adjobimey M, Cook VJ, Fisher D, Fox GJ, Fregonese F, Hadisoemarto P, Hill PC, Johnston J, Long R, Obeng J, Ruslami R, Valiquette C, Menzies. Enhancing the public health impact of latent tuberculosis infection diagnosis and treatment (ACT4): protocol for a cluster randomised trial. BMJ Open. 2019 Mar 20;9(3):e025831
46. Ugarte-Gil C, Alisjahbana B, Ronacher K, Riza AL, Koesoemadinata RC, Malherbe ST, Cioboata R, Llontop JC, Kleynhans L, Lopez S, Santoso P, Marius C, Villaizan K, Ruslami R, Walzl G, Panduru NM, Dockrell HM, Hill PC, Mc Allister S, Pearson F, Moore DAJ, Critchley JA, van Crevel R; TANDEM Consortium. Diabetes mellitus among pulmonary tuberculosis patients from four TB-endemic countries: the TANDEM study. Clin Infect Dis. 2019 Apr 8. pii: ciz284. doi: 10.1093/cid/ciz284. [Epub ahead of print]
47. Stemkens R, Litjens CHC, Dian S, Ganiem AR, Yunivita V, van Crevel R, Te Brake LHM, Ruslami R, Aarnoutse RE. Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment. nt J Antimicrob Agents. 2019 Jun 13. pii: S0924-8579(19)30163-3. doi: 10.1016/j.ijantimicag.2019.06.010. [Epub ahead of print]
48. Verrall AJ, Alisjahbana B, Apriani L, Novianty N, Nurani AC, van Laarhoven A, Ussher JE, Indrati A, Ruslami R, Netea MG, Sharples K, van Crevel R, Hill PC. Early Clearance of Mycobacterium tuberculosis: The INFECT Case Contact Cohort Study in Indonesia. J Infect Dis. 2019 Jul 12. pii: jiz168. doi: 10.1093/infdis/jiz168. [Epub ahead of print].
49. Berbudi A, Rahmadika N, Cahyadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev. 2019 Oct 23. doi: 10.2174/1573399815666191024085838. [Epub ahead of print]
50. Svensson EM, Dian S, Te Brake L, Ganiem AR, Yunivita V, van Laarhoven A, van Crevel R, Ruslami R, Aarnoutse RE. Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculosis meningitis trials. Clin Infect Dis. 2019 Oct 30. pii: ciz1071. doi: 10.1093/cid/ciz1071. [Epub ahead of print]
51. McAllister SM, Koesoemadinata RC, Santoso P, Soetedjo NNM, Kamil A, Permana H, Ruslami R, Critchley JA, van Crevel R, Hill PC, Alisjahbana B. High tuberculosis incidence among people living with diabetes in Indonesia. Trans R Soc Trop Med Hyg. 2019 Nov 11. pii: trz100. doi: 10.1093/trstmh/trz100. [Epub ahead of print]
52. Menzies D, Cook V, Long R, Ruslami R. No evidence of increased risk of acquired rifampin resistance. CMAJ. 2019 Nov 25;191(47):E1314-E1315. doi: 10.1503/cmaj.73353
53. Ruesen C, Chaidir L, Ugarte-Gil C, van Ingen J, Critchley JA, Hill PC, Ruslami R, Santoso P, Huynen MA, Dockrell HM, Moore DAJ, Alisjahbana B, van Crevel R. Diabetes is associated with genotypically drug-resistant tuberculosis. Eur Respir J. 2019 Dec 12. pii: 1901891. doi: 10.1183/13993003.01891-2019. [Epub ahead of print]
54. Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, Eisenbeis L, Fregonese F, Valiquette C, Benedetti A, Menzies D. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis. 2019 Dec 19. pii: S1473-3099(19)30575-4. doi: 10.1016/S1473-3099(19)30575-4. [Epub ahead of print]

National Publication
1. Triana Nurul Meirina, Atu Purnama Dewi, Harold Eka Atmaja, Vycke Yunivita Kusumah Dewi, Rovina Ruslami: Analisis Glikosida Kardioaktif Digoksin Menggunakan Ultra Performance Liquid Chromatography (UPLC). Jurnal Chimica et Natura Acta, 2014;2 (1)
2. Lastri Mei Winarni, Tina Dewi Judistiani, Rovina Ruslami, Farid Husin, Endang Sutedja, Dewi M. D. Herawati, Ponpon S. Idjradinata: Penggunaan Model CIPP dalam Evaluasi Kurikulum Inti Pendidikan D-III Kebidanan, 2014;1(1)
3. Putri MV, Ruslami R, Apriani L. Health Seeking Behavior among Patients with Tuberculosis in Dr. Hasan Sadikin General Hospital Bandung, Indonesia in November 2012. Althea Medical Journal. Sept 2015;3:418-12.
4. Adi Imam Cahyadi, Rovina Ruslami, Sunaryati Sudigdoadi: Studi Kualitas Air Reserve Osmosis Secara Mikrobiologi pada Dua Unit Hemodialis di Kota Bandung. Jurnal Sistem Kesehatan, 2016; 3(1): 113-119
5. Ruslami R, Rosalita R, Yolanda R, Agustin A, Sudigdoadi. Potensi Suplementasi Resveratrol dalam Mengatasi Efek Negatif Hormon Tiroid pada Terapi Obesitas: Uji Preklinik. Majalah Kesehatan Bandung. 2016;48(1):51–7.
6. Andriane Y, Sastramihardja HS, Ruslami R. Determinan Peresepan Polifarmasi pada Resep Rawat Jalan di Rumah Sakit Rujukan. Global Medical and Health Communication, 2016;4(1):66-74
7. Ruslami R, Bisri T. Penggunaan Obat Anti Epilepsi untuk Terapi Profilaksis Bangkitan pada Cedera Otak Traumatik. Journal Neuroanestesi Indonesia 2016;5(1):77–85.
8. Ulfah Dwi Fibriani, Rovina Ruslami, Bachti Alisjahbana. Level of Knowledge about Tuberculosis among Type 2 Diabetes Mellitus Patients at the Endocrine Clinic Dr. Hasan Sadikin General Hospital Bandung. Althe Med Journal. 2017; 4(3):512-7